Stock comparison
ELI LILLY & Co is 20.1x more valuable than REGENERON PHARMACEUTICALS, INC. by market capitalization ($1.142 T vs $56.80 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
LLY is larger
ELI LILLY & Co is 20.1x more valuable than REGENERON PHARMACEUTICALS, INC. by market capitalization ($1.142 T vs $56.80 B).
Market value leader
LLY
ELI LILLY & Co is 20.1x more valuable than REGENERON PHARMACEUTICALS, INC. by market capitalization ($1.142 T vs $56.80 B).
Revenue leader
LLY
REGN: $14.34B vs LLY: $65.18B.
Profit leader
LLY
REGN: $4.50B vs LLY: $20.64B.
Margin leader
LLY
REGN: 31.4% vs LLY: 31.7% net margin.
| Metric | REGN | LLY |
|---|---|---|
| Market cap | $56.80 B | $1.142 T |
| US-listed rank | #291 | #10 |
| Revenue (latest FY) | $14.34B | $65.18B |
| Net income (latest FY) | $4.50B | $20.64B |
| Net margin | 31.4% | 31.7% |
| P/E (trailing FY) | 12.6x | 55.3x |
| SEC filings | 985 | 995 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
ELI LILLY & Co is 20.1x more valuable than REGENERON PHARMACEUTICALS, INC. by market capitalization ($1.142 T vs $56.80 B).
In their latest fiscal years, REGENERON PHARMACEUTICALS, INC. reported $14.34B in revenue while ELI LILLY & Co reported $65.18B.
Full pages: REGENERON PHARMACEUTICALS, INC. and ELI LILLY & Co, or browse the full rankings.